文献速递骨软组织肉瘤与黑色素瘤

黑色素瘤中的MAPK通路第二部分——BRAF抑制的继发性和适应性耐药机制

MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
PubMed 文献 · Eur J Cancer · 2017-02-03

约45%的转移性黑色素瘤患者可检测到BRAF突变,BRAF和MEK抑制剂能诱导快速反应并延长生存,但相当比例患者会出现耐药和疾病进展。MAPK通路是BRAF/MEK抑制耐药中最重要的通路,尤其是MAPK通路再激活。本文综述继发性和适应性耐药机制,并提及BRAF抑制改变免疫反应,靶向联合免疫治疗可改善反应但可能存在交叉耐药。

要点

  • 约45%的转移性黑色素瘤患者可检测到BRAF突变。
  • BRAF和MEK抑制剂可诱导快速反应并延长生存,但相当比例患者出现耐药和疾病进展。
  • MAPK通路再激活是BRAF/MEK抑制耐药中最重要的机制。

核心结论

  • 本文综述BRAF/MEK抑制的继发性和适应性耐药机制,强调MAPK通路再激活是最重要的耐药机制。

研究设计与样本

  • 综述,聚焦BRAF/MEK抑制的继发性和适应性耐药机制。

主要发现

  • 约45%的转移性黑色素瘤患者可检测到BRAF突变。
  • BRAF和MEK抑制剂能诱导快速反应并延长生存,但相当比例患者会出现耐药和疾病进展。
  • 耐药机制可分为原发性或内在性(对治疗无反应)、继发性或获得性(肿瘤退缩一段时间后MAPK通路再激活)和适应性(初始反应后早期耐药)。
  • BRAF抑制改变免疫反应,靶向联合免疫治疗可改善反应,但可能存在交叉耐药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BRAF mutation can be identified in about 45% of the patients with metastatic melanoma. In these patients, BRAF and MEK inhibitors are able to induce rapid responses and to prolong survival. However, a significant percentage of patients will develop resistance to targeted therapy and will have progressive disease. MAPK pathway is the most important pathway involved in BRAF/MEK inhibition resistance, particularly MAPK pathway reactivation. Resistance mechanisms can be classified as 1) primary or intrinsic characterised by no response to therapy, 2) secondary or acquired with MAPK pathway reactivation after a time of tumour regression and 3) as adaptive with initial response and early resistance. BRAF inhibition also alters the immune response. Several publications have described immune effects of BRAF inhibition in melanoma tumours, showing that combining targeted and immunotherapy can improve response, despite a possible cross-resistance. Here, we continue the review on resistance mechanisms to BRAF/MEK inhibition and focus on the secondary and adaptive mechanisms.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Amaral T, Sinnberg T, Meier F, et al. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. Eur J Cancer. 2017. PMID: 28162869. doi:10.1016/j.ejca.2016.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。